MRTX Mirati Therapeutics Options Ahead of EarningsAnalyzing the options chain and the chart patterns of MRTX Mirati Therapeutics prior to the earnings report this week,
I would consider purchasing the 35usd strike price Puts with
an expiration date of 2023-9-15,
for a premium of approximately $0.57.
If these options prove to be profitable prior to the earnings release, I would sell at least half of them.
Looking forward to read your opinion about it.
MRTX
Mirati Therapeutics (NASDAQ: $MRTX) Flashes Signs Of Reversal 🚦Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Mirati Therapeutics good news. The price will start to rise soonI spent about 3 hours researching this company and I will divide my work into 3 parts. Last report, other positive news, and why you shouldn't open long position right now. Enjoy reading.
1) Mirati Therapeutics Reports First Quarter 2021 Financial Results (May 06, 2021)
The most important information:
- Initiated potentially registration-enabling trials evaluating our investigational KRASG12C inhibitor, adagrasib, in lung and colorectal cancers, as monotherapy and with other agents - POSITIVE NEWS
- Plan to file an Investigational New Drug (IND) application in 2022 for our investigational KRASG12D inhibitor, MRTX1133 - POSITIVE NEWS
- Presented preclinical data at AACR 2021 on an investigational synthetic lethal methylthioadenosine (MTA) cooperative PRMT5 inhibitor - POSITIVE NEWS
- Research and development expenses for the first quarter of 2021 were $104.1 million, compared to $71.7 million for the same period in 2020. !!!!!!!!!! - IMPORTANT
2) Other positive news (Jun 01, 2021)
- Mirati Therapeutics and Zai Lab Enter Into a Collaboration to Develop and Commercialize Adagrasib in Greater China
- Mirati to receive an upfront payment of $65 million, up to approximately $273 million in potential milestone payments and high-teen- to low-twenties-percent tiered royalties
3) Why you shouldn't open long position right now
First, there are too many resistance lines at the moment. I doubt that the price will suddenly rise now and break through all resistance lines.
After the May report, the price did not break the white resistance line. Most likely, the next report will raise the price and in my opinion, there is a good chance that it will end the bear market this year.
MRTX - SWING ANALYSISMRTX - As per the breakout happened with the volumes also coming in it is expected to go more high from the current levels.
Buy here at current price 209
Maintain stop loss around 194
Target upside 218- 234
Hit the like button to get more signals, Thanks
Recently CLOSED Trades - Stock Trading RecapHello everyone,
I have got here for you some of our recently closed trades on our long-term strategy. Check in the video how we analyzed the markets, what was the logic behind and how the trades developed eventually.
Tickers:
NASDAQ:MRTX
NYSE:AQN
NYSE:BGS
John
FINEIGHT Team
MRTX - Fallen angel breakout long from $4.43 to $5.93MRTX was discussed in the trading room last Thursday, and considered a long entry at $4.07 area. It went up 11% today. So how into it should be in good profit.
Who missed it, can look for a break of $4.43 & take a ride. It has good insider buying & it seem it has very strong upside potential.
* Trade Criteria *
Date First Found- July 17, 2017
Pattern/Why- Fallen angel pattern long
Entry Target Criteria- Break of $4.43
Exit Target Criteria- $5.93
Stop Loss Criteria- $3.97
Please check back for Trade updates. (Note: Trade update is little delayed here.)
MRTX - Fallen angel pattern long from $4.07 to $4.93MRTX forming a nice fallen angel formation. It is breaking through it moving averages. If it can break above $4.07 it can easily go to $5 area.
* Trade Criteria *
Date First Found- June 21, 2017
Pattern/Why- Fallen angel pattern
Entry Target Criteria- Break of $4.07
Exit Target Criteria- $4.93
Stop Loss Criteria- N/A
Please check back for Trade updates. (Note: Trade update is little delayed here.)
MRTX - Long from 5.43 to 7.44 & above MRTX forming a fallen angel pattern, just scooping through the moving averages now. Also great money-flow divergence, seems ready to run upward.
Possible entry criteria 5.43 to target 7.44 and Stop Criteria 4.87. we would tighten the stop after a further rally to $5.13
MRTX - Long from 5.37 or 5.71 which meet first MRTX forming a fallen angel pattern, just scooping through the moving averages now. Also great money-flow divergence, seems ready to run upward.
We are considering two possible entry, either pull back to 5.37 or break above 5.71 & two target of 6.83 & 9.77
You can check our detailed analysis on MRTX in the trading room/ Executive summery link here-
www.youtube.com
Time Span: 6:00"
Trade Status: Pending